24,905 results match your criteria Hematology/oncology clinics of North America[Journal]


Co-existing Bilateral Pulmonary Embolism and Intra-cardiac Mass: A Case of Catastrophic Antiphospholipid Syndrome-like Disease.

Cureus 2018 Oct 10;10(10):e3438. Epub 2018 Oct 10.

Internal Medicine, Shifa International Hospital, Islamabad, PAK.

Young patients presenting with thrombotic events like pulmonary embolism and cardiological phenomenon such as presence of an intracardiac mass, without any underlying risk factors, should be promptly investigated for thrombophilias including antiphospholipid syndrome (APLS). This case is reported to highlight rare occurrence of co-existing bilateral extensive pulmonary embolism and an intra-cardiac mass at presentation of antiphospholipid syndrome as well as progression to near catastrophic APLS. Read More

View Article
October 2018

Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.

Oncoimmunology 2019 11;8(1):e1512455. Epub 2018 Oct 11.

Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor outcomes, emphasizing the need for newer therapeutic agents. Bruton's tyrosine kinase (BTK) is activated following B-cell receptor stimulation and in part regulates normal B-cell development. Ibrutinib, a selective and irreversible BTK inhibitor, has been efficacious in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. Read More

View Article
October 2018
1 Read

Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant 2018 Dec 13. Epub 2018 Dec 13.

Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had ≥1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n = 1492), 31% (n = 824), and 13% (n = 340) of total BSI, respectively. Read More

View Article
December 2018

Introduction to the Special Issue on Pediatric Neuro-Oncology.

Bioengineering (Basel) 2018 Dec 11;5(4). Epub 2018 Dec 11.

Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Pediatric Neuro-Oncology is a highly specialized field encompassing molecular biology, clinical acumen, evidence based medicine, cancer genetics and neuropsychological care for the diagnosis and treatment of children with central nervous system (CNS) tumors. [.. Read More

View Article
December 2018

A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.

PLoS One 2018 13;13(12):e0208936. Epub 2018 Dec 13.

Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University's Feinberg School of Medicine and Robert H. Lurie Cancer Center, Chicago, Illinois, United States of America.

This study explores the genomic alterations that contribute to the formation of a unique subset of low-risk, epithelial differentiated, favorable histology Wilms tumors (WT), tumors that have been characterized by their expression of post-induction renal developmental genes (Subset 1 WT). We demonstrate copy neutral loss of heterozygosity involving 19q13.32-q13. Read More

View Article
December 2018

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

JAMA Oncol 2018 Dec 13:e184475. Epub 2018 Dec 13.

Department of Medicine, University of California at San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco.

Importance: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor-positive (ER+), endocrine therapy-resistant breast cancers.

Objective: To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibitor, plus fulvestrant in patients with ER+ advanced breast cancer (ABC).

Design, Setting, And Participants: An open-label, single-arm, phase 1b study of alpelisib plus fulvestrant was conducted at 10 centers in 5 countries. Read More

View Article
December 2018

A Rare Instance of Simultaneous Infection with Disseminated Nocardia and Pulmonary Aspergillus in a Patient Receiving Treatment with Ibrutinib for Chronic Lymphocytic Leukemia.

Cureus 2018 Oct 8;10(10):e3427. Epub 2018 Oct 8.

Infectious Disease, Joan C. Edwards School of Medicine - Marshall University, Huntington, USA.

Disseminated Nocardia infections are a rare occurrence that typically occur in immunocompromised hosts. Chronic lymphocytic leukemia (CLL) is a hematologic malignancy which makes patients susceptible to infections through various mechanisms. The treatments for CLL also target immunologic pathways which can contribute to infections. Read More

View Article
October 2018

A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

Genet Med 2018 Dec 13. Epub 2018 Dec 13.

Departments of Pathology & Laboratory Medicine and Medical Genetics, Alberta Children's Hospital Research Institute and Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Purpose: Kaposiform lymphangiomatosis (KLA) is a rare, frequently aggressive, systemic disorder of the lymphatic vasculature, occurring primarily in children. Even with multimodal treatments, KLA has a poor prognosis and high mortality rate secondary to coagulopathy, effusions, and systemic involvement. We hypothesized that, as has recently been found for other vascular anomalies, KLA may be caused by somatic mosaic variants affecting vascular development. Read More

View Article
December 2018

Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells.

Oncogene 2018 Dec 12. Epub 2018 Dec 12.

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Penn State Health Hershey Medical Center, Penn State College of Medicine, Hershey, PA, 17033, USA.

Glioblastoma (GBM) is the most aggressive brain tumor and resistant to current available therapeutics, such as radiation. To improve the clinical efficacy, it is important to understand the cellular mechanisms underlying tumor responses to radiation. Here, we investigated long-term cellular responses of human GBM cells to ionizing radiation. Read More

View Article
December 2018

Immune T cells can transfer and boost anti-breast cancer immunity.

Oncoimmunology 2018 27;7(12):e1500672. Epub 2018 Aug 27.

Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA.

This proof-of-concept study investigates the immune effects in metastatic breast cancer (MBC) patients after "vaccination" with activated T cells (ATC) armed with anti-CD3 x anti-HER2 bispecific antibody (HER2 BATs) followed by immune consolidation with immune ATC "boost" after high dose chemotherapy (HDC) and autologous stem cell transplant (SCT). Approximately 2 weeks after completion of vaccination portion of the study, immune T cells were obtained by leukopheresis, activated and expanded and re-infused after HDC and SCT to test the hypothesis that transfer of immune unarmed ATC would accelerate reconstitution of anti-tumor activity after SCT. Eight metastatic breast cancer (MBC) patients received 8 infusions of HER2 BATs, low dose IL-2, and GM-CSF in the first part of the protocol to induce adaptive cellular and humoral responses. Read More

View Article
August 2018
1 Read

HPV-Associated Anal Cancer in the HIV/AIDS Patient.

Cancer Treat Res 2019 ;177:183-209

Division of Infectious Diseases, Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.

The prevalence of anal human papillomavirus (HPV) infection and anal high-grade squamous intraepithelial lesion (HSIL) remain high among HIV-infected individuals on effective antiretroviral therapy (ART). The incidence of HPV-related anal cancers has continued to increase since the introduction of ART. Therefore, ART may confer only limited benefit with respect to reducing the risk of anal HSIL and cancer. Read More

View Article
January 2019

HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.

Haematologica 2018 Dec 6. Epub 2018 Dec 6.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Second allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for patients with hematologic malignancies. However, it is unclear whether HLA discrepancy between graft and first donor has an impact on the outcome of second HSCT. We retrospectively analyzed 646 patients receiving second HSCT after an initial HLA mismatched (MM) transplantation. Read More

View Article
December 2018

Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients.

Mol Cancer Ther 2018 Dec 6. Epub 2018 Dec 6.

Center for Personalized Cancer Therapy, UCSD Moores Cancer Center.

Inhibitors of the PD-1/PD-L1/CTLA4 immune checkpoint pathway have revolutionized cancer treatment. Indeed, some patients with advanced, refractory malignancies achieve durable responses; however, only a subset of patients benefit, necessitating new biomarkers to predict outcome. Interrogating cell-free DNA (cfDNA) isolated from plasma (liquid biopsy) provides a promising method for monitoring response. Read More

View Article
December 2018

Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome.

J Pharmacol Sci 2018 Nov 24. Epub 2018 Nov 24.

Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan; Department of General Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan.

Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS). Since pioglitazone is known to have anti-inflammatory property, we hypothesized that pioglitazone is beneficial for treating IBS. In this study, the effect was tested in rat IBS models such as lipopolysaccharide or repeated water avoidance stress-induced visceral allodynia and increased colonic permeability. Read More

View Article
November 2018

Differential Gene Expression in Erlotinib-treated Fibroblasts.

Nurs Res 2018 Dec 12. Epub 2018 Dec 12.

Assistant Professor, University of South Carolina, College of Nursing, Columbia, SC Bioinformatics Analyst I, University of Maryland, Baltimore, School of Medicine, Institute for Genome Sciences, Baltimore, MD Professor, Chair, Department of Hematology/Oncology, Deputy Director of the Cancer Center for Clinical Research, G. Morris Dorrance Chair in Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA Bioinformatics Analyst II, University of Maryland, School of Medicine, Institute for Genome Sciences, Baltimore, MD Laboratory Research Technician, University of Maryland, Baltimore, School of Nursing, Baltimore, MD Professor, Chair, Department of Pain and Translational Symptom Science, University of Maryland, Baltimore, School of Nursing, Baltimore, MD.

Background: Therapies targeting the epidermal growth factor receptor (EGFR) result in a painful rash, the most common and debilitating toxicity among patients with non-small cell lung cancer (NSCLC) who take EGFR tyrosine kinase inhibitor (TKI) therapy; however, predicting the development and the severity of the rash is difficult.

Objective: To examine how erlotinib-an EGFR TKI that NSCLC patients take to stop or slow tumor growth-altered the transcriptome of dermal fibroblasts.

Methods: Dermal fibroblasts (ATCC® PCS-201-012™) were seeded in cell culture flasks, grown under standard conditions, and transferred to cell culture dishes. Read More

View Article
December 2018

Successful medical treatment for a Crohn's disease patient with a perforation by a second-generation patency capsule.

Endosc Int Open 2018 Dec 10;6(12):E1436-E1438. Epub 2018 Dec 10.

Division of Gastroenterology and Hematology/Oncology Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.

 Symptomatic capsule retention is a very rare adverse event following patency capsule, and the vast majority of cases are resolved without either surgical or endoscopic intervention. We herein describe a rare case of small bowel perforation after swallowing a patency capsule in a 37-year-old man suspected of having Crohn's disease. Read More

View Article
December 2018

Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins.

Cancer Res 2018 Dec 11. Epub 2018 Dec 11.

Medicine, University of California, San Francisco

Chromosomal rearrangements involving receptor tyrosine kinases (RTK) are a clinically relevant oncogenic mechanism in human cancers. These chimeric oncoproteins often contain the C-terminal kinase domain of the RTK joined in cis to various N-terminal, non-kinase fusion partners. The functional role of the N-terminal fusion partner in RTK fusion oncoproteins is poorly understood. Read More

View Article
December 2018

Specialized pediatric palliative care services for children dying from cancer: A repeated cohort study on the developments of symptom management and quality of care over a 10-year period.

Palliat Med 2018 Dec 12:269216318818022. Epub 2018 Dec 12.

1 Paediatric Palliative Care Centre and German Paediatric Pain Centre, Children's and Adolescents' Hospital, Datteln, Germany.

Background:: About one quarter of children affected with cancer die. For children and their families, the end-of-life period is highly distressing.

Aim:: This study focused on how end-of-life care in pediatric cancer patients changed over a period of 10 years and if changes in pediatric palliative care structures were associated with quality of care. Read More

View Article
December 2018

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor/Recipient Pairs with Improved Transplant Outcome.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Diagnostic Laboratories and Blood Research Institute, BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI. Electronic address:

HLA matching by allele-level genotyping is largely based on genetic similarity between a few exons which encode the antigen recognition domain (ARD) of the HLA protein. Next-generation sequencing (NGS) can identify HLA genetic polymorphisms in non-ARD encoding exons, introns, and untranslated regions, but the impact of these polymorphisms on hematopoietic cell transplant (HCT) outcomes is unclear. We performed NGS-based sequencing of eleven HLA loci on a well-characterized retrospective cohort of 166 unrelated donor/recipient HCT pairs. Read More

View Article
December 2018
1 Read

Lens dose-response prediction modeling and cataract incidence in retinoblastoma patients after lens-sparing or whole-eye radiotherapy.

Int J Radiat Oncol Biol Phys 2018 Dec 8. Epub 2018 Dec 8.

Department of Radiation Oncology, Keck School of Medicine of USC and Children's Hospital Los Angeles, Los Angeles, CA. Electronic address:

Purpose: We retrospectively assessed the incidence of cataracts in retinoblastoma (Rb) patients treated with either lens-sparing (LSRT) or whole-eye radiotherapy (WERT). A secondary aim of this study was to model the dose-response risk of cataract.

Methods: We reviewed 65 retinoblastoma patients treated with radiotherapy (RT) at XXXX from 1997-2015. Read More

View Article
December 2018

Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians.

J Oncol Pract 2018 Dec;14(12):e758-e769

Sarah Cannon Cancer Institutes at HCA Midwest Health, Overland Park, KS; University of Florida College of Medicine; Malcom Randall Veterans Affairs Medical Center, Gainesville; Florida Cancer Specialists, Deland, FL; University of Texas Southwestern Medical Center, Dallas, TX; and Cleveland Clinic Akron General, Akron, OH.

Purpose:: Meaningful connections are an important aspect of career satisfaction. The Hematology Oncology Women Physician Group (HOWPG) is a private Facebook (FB) group of 936 women who practice within the hematology/oncology (H/O) field. We hypothesized that HOWPG adds value to education, emotional wellness, and practice of oncology for its membership. Read More

View Article
December 2018
1 Read

Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature.

Pediatr Blood Cancer 2018 Dec 10:e27569. Epub 2018 Dec 10.

Department of Pediatrics, Hematology/Oncology Section, Baylor College of Medicine, Houston, Texas.

Autoimmune cytopenias (AIC) post-hematopoietic stem cell transplant (HSCT) are rare but exceptionally challenging complication. We conducted a comprehensive literature review and identified a pooled incidence of post-HSCT autoimmune hemolytic anemia and/or immune thrombocytopenia of 2.66% (SE = 0. Read More

View Article
December 2018

Lung function impairment in pediatric patients with sickle cell anemia from Nigeria is associated with low steady state hemoglobin.

Am J Hematol 2018 Dec 8. Epub 2018 Dec 8.

Department of Pediatric Haematology, Evelina Children's Hospital, Guy's and St. Thomas NHS Trust, London, United Kingdom.

View Article
December 2018

Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.

Eur J Cancer Care (Engl) 2018 Dec 10:e12976. Epub 2018 Dec 10.

Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Lin-Ko, Taiwan.

The purpose of this study was to evaluate the longitudinal incidence, severity, pattern of changes or predictors of oxaliplatin-induced peripheral neuropathy (OXAIPN) in Taiwanese patients with colorectal cancer. A longitudinal repeated measures study design was employed, and 77 participants were recruited from the colorectal and oncology departments of two teaching medical centres in Taiwan. Physical examinations were performed, and self-reports regarding adverse impacts of OXAIPN and quality of life were obtained at five time points throughout 12 cycles of chemotherapy (C/T). Read More

View Article
December 2018
1 Read

Medulloblastoma and secondary acute myeloid leukemia in a patient with Turner syndrome.

Pediatr Blood Cancer 2018 Dec 10:e27576. Epub 2018 Dec 10.

Division of Hematology/Oncology, Department of Pediatrics, Nemours/A.I duPont Hospital for Children, Thomas Jefferson University, Wilmington, Delaware.

View Article
December 2018
1 Read

Flow Cytometry-Based Detection and Analysis of BCL-2 Family Proteins and Mitochondrial Outer Membrane Permeabilization (MOMP).

Methods Mol Biol 2019 ;1877:77-91

Section of Hematology/Oncology/Stem Cell Transplantation and Committee on Cancer Biology, Department of Pediatrics, University of Chicago, Chicago, IL, USA.

The BCL-2 family of proteins orchestrates a complex signaling network that governs the balance between cellular survival and death. A comprehensive understanding of the mechanistic interactions between these proteins continues to evolve in normal and malignant cells. The functional variation by individual BCL-2 proteins in different cell types has driven clinical therapeutic development in targeting individual BCL-2 members with the goal of fine-tuning cell death in diseased cells. Read More

View Article
January 2019

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.

Cancer Chemother Pharmacol 2018 Dec 8. Epub 2018 Dec 8.

CELLTRION Healthcare Co. Ltd, Incheon, Republic of Korea.

Purpose: To investigate the safety and efficacy of 30-min maintenance infusions of trastuzumab in advanced gastric cancer positive for human epidermal growth factor receptor 2 (HER2).

Methods: This was a retrospective study conducted across five Korean hospitals in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma treated with first-line, 3-weekly trastuzumab plus chemotherapy. The first dose of trastuzumab (8 mg/kg) was administered as a 90-min infusion, with all subsequent maintenance infusions (6 mg/kg) given over 30 min. Read More

View Article
December 2018

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ.

NPJ Breast Cancer 2018 5;4:39. Epub 2018 Dec 5.

1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC USA.

Serial monitoring of plasma DNA mutations in estrogen receptor positive metastatic breast cancer (ER + MBC) holds promise as an early predictor of therapeutic response. Here, we developed dPCR-SEQ, a customized assay that utilizes digital PCR-based target enrichment followed by next-generation sequencing to analyze plasma DNA mutations in , , and . We validated dPCR-SEQ in a prospective cohort of 58 patients with ER + MBC and demonstrate excellent concordance with hotspot mutation abundance measured by conventional digital PCR. Read More

View Article
December 2018

Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.

Mol Ther Methods Clin Dev 2018 Dec 1;11:167-179. Epub 2018 Nov 1.

Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Sickle cell disease (SCD) is caused by a mutation (E6V) in the hemoglobin (Hb) β-chain that induces polymerization of Hb tetramers, red blood cell deformation, ischemia, anemia, and multiple organ damage. Gene therapy is a potential alternative to human leukocyte antigen (HLA)-matched allogeneic hematopoietic stem cell transplantation, available to a minority of patients. We developed a lentiviral vector expressing a β-globin carrying three anti-sickling mutations (T87Q, G16D, and E22A) inhibiting axial and lateral contacts in the HbS polymer, under the control of the β-globin promoter and a reduced version of the β-globin locus-control region. Read More

View Article
December 2018

Microvasculature-on-a-chip for the long-term study of endothelial barrier dysfunction and microvascular obstruction in disease.

Nat Biomed Eng 2018 23;2:453-463. Epub 2018 Apr 23.

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.

Alterations in the mechanical properties of erythrocytes occurring in inflammatory and hematologic disorders such as sickle cell disease (SCD) and malaria often lead to increased endothelial permeability, haemolysis, and microvascular obstruction. However, the associations among these pathological phenomena remain unknown. Here, we report a perfusable, endothelialized microvasculature-on-a-chip featuring an interpenetrating-polymer-network hydrogel that recapitulates the stiffness of blood-vessel intima, basement membrane self-deposition and self-healing endothelial barrier function for longer than 1 month. Read More

View Article
April 2018
1 Read

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.

Oncotarget 2018 Nov 9;9(88):35809-35812. Epub 2018 Nov 9.

Foundation Medicine, Inc. Cambridge, MA, USA.

CGP results from >60,000 cases were screened to identify NTRK fusion events from cases of neuroendocrine tumors. 2417 NET patients from diverse anatomic sites were identified. From this dataset, six cases harbored NTRK fusions which included intra- and inter-chromosomal translocations. Read More

View Article
November 2018
1 Read

Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide.

Saudi Pharm J 2018 Dec 20;26(8):1162-1169. Epub 2018 Jul 20.

Science and Technology Unit, Umm Al Qura University, Makkah 21955, Saudi Arabia.

Cancer may be difficult to target, however, if cancer targeted this provides the chance for a better and more effective treatment. uantum dots (Qdots) coated vapreotide (VAP) as a somatostatin receptors (SSTRs) agonist can be efficient targeting issue since may reduce side effects and increase drug delivery to the target tissue. This study highlights the active targeting of cancer cells by cells imaging with improving the therapeutic outcomes. Read More

View Article
December 2018

Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning.

Bone Marrow Transplant 2018 Dec 7. Epub 2018 Dec 7.

Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Reduced-intensity conditioning is widely used with hematopoietic stem cell transplantation for non-malignant diseases: however, the optimal conditioning to ensure stable engraftment has not been established. In this study, we retrospectively compared the impact of low-dose (1-6 Gy) irradiation and in vivo T-cell depletion on the clinical outcome of 523 patients with non-malignant disease who underwent a first allogeneic hematopoietic stem cell transplantation using fludarabine-based reduced-intensity conditioning. Use of low-dose irradiation, but not of anti-thymocyte globulin/anti-lymphocyte globulin, showed a beneficial effect on overall survival (adjusted hazard ratio: 0. Read More

View Article
December 2018

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Bone Marrow Transplant 2018 Dec 7. Epub 2018 Dec 7.

Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Read More

View Article
December 2018

Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Bone Marrow Transplant 2018 Dec 7. Epub 2018 Dec 7.

Department of Ophthalmology, University Clinical Hospital Zagreb, Zagreb, Croatia.

Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity, which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Read More

View Article
December 2018

A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant.

J Pediatr Hematol Oncol 2018 Dec 7. Epub 2018 Dec 7.

Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT.

Myoepithelial carcinomas (MC) represent aggressive tumors that occur in a myriad of ages and anatomic locations. The rarity and histologic similarity with other tumors make them difficult to diagnosis. We report an extremely rare case of a right ventricular outflow tract mass identified to be an intracardiac MC in a 4-month-old male infant. Read More

View Article
December 2018

Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection?

Pancreas 2019 Jan;48(1):e1-e3

Division of Endocrinology Department of Medicine The University of Arizona College of Medicine Tucson, AZ Division of Hematology/Oncology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas, TX Division of Surgical Oncology Department of Surgery University of Texas Southwestern Medical Center Dallas, TX Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas, TX Touchstone Diabetes Center Department of Internal Medicine University of Texas Southwestern Medical Center Dallas, TX Division of Hematology/Oncology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas, TX

View Article
January 2019
1 Read

Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Blood 2018 Dec 7. Epub 2018 Dec 7.

Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective therapy for CLL patients. To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single center trial of ibrutinib versus ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28 day cycles of once-daily ibrutinib 420 mg, either as single agent (n=104), or together with rituximab (375 MG/m, n=104), given weekly during cycle 1, then once per cycle until cycle 6. Read More

View Article
December 2018

Endophthalmitis incidence of cancer patients after cataract surgery: A nationwide matched cohort study in Taiwan.

Am J Ophthalmol 2018 Dec 5. Epub 2018 Dec 5.

Department of Public Health, College of Medicine, Chang Gung University, Taiwan; Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital at Linkou, Taiwan; Biostatistics Core Laboratory, Molecular Medicine Research Center, Chang Gung University, Taiwan. Electronic address:

Purpose: To compare the incidence rate of endophthalmitis after cataract surgery between cancer cohort and matched non-cancer cohort.

Design: matched cohort study METHODS: Patients with cataract surgery of both eyes among a nationwide cancer cohort and 1:1 matched non-cancer cohort were enrolled from the year of 1998 to 2012 in Taiwan National Health Insurance Research Database. Both the cancer group and the control group were followed for three months after the cataract surgery to obtain the rate of endophthalmitis. Read More

View Article
December 2018
2 Reads

Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose TBI/G-CSF-combined cytarabine in single cord blood transplantation for elderly patients with non-remission myeloid malignancies.

Biol Blood Marrow Transplant 2018 Dec 7. Epub 2018 Dec 7.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

The optimal intensity of a conditioning regimen might be dependent on not only age and comorbidities, but also disease activity and the type of graft source. We evaluated the outcome of unrelated single cord blood transplantation (CBT) using a conditioning regimen of fludarabine 180 mg/m, intravenous busulfan 9.6 mg/kg, 4 Gy total body irradiation, granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine (Ara-C) (12 g/m) in 23 elderly patients (median, 64 years) with non-remission myeloid malignancies between 2013 and 2018 in our institution. Read More

View Article
December 2018

Temporal Trends of Pediatric Hospitalizations with Acute Disseminated Encephalomyelitis in the United States: An Analysis from 2006 to 2014 using National Inpatient Sample.

J Pediatr 2018 Dec 6. Epub 2018 Dec 6.

Department of Pediatrics, Tulane University, New Orleans, LA; Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX.

Objective: To determine the temporal trends in the epidemiology of acute disseminated encephalomyelitis (ADEM) and hospitalization outcomes in the US from 2006 through 2014.

Study Design: Pediatric (≤18 years of age) hospitalizations with ADEM discharge diagnosis were identified from the National (Nationwide) Inpatient Sample (NIS) for years 2006 through 2014. Trends in the incidence of ADEM with respect to age, sex, race, and region were examined. Read More

View Article
December 2018

Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation.

J Pediatr 2018 Dec 7. Epub 2018 Dec 7.

Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH.

Objective: To investigate treatment-related outcomes, namely radiological clot resolution, post-thrombotic syndrome (PTS), and health related quality-of-life (HRQoL) scores, in children with Paget-Schroetter syndrome (PSS) undergoing multidisciplinary management, including anticoagulation and decompressive rib-resection surgery, with or without thrombolytic therapy.

Study Design: We identified all patients treated for PSS at our institution between the years 2010 and 2017. Baseline clinical and radiologic data were abstracted from medical records. Read More

View Article
December 2018
3.790 Impact Factor

Pediatric oncology nurses' perceptions of prognosis-related communication: A qualitative report.

Nurs Outlook 2018 Nov 15. Epub 2018 Nov 15.

Duke University School of Nursing, Durham, NC (published posthumously: DOD July 7, 2018).

Background: Disclosure of prognosis-related information is an essential aspect of communication with pediatric patients with cancer and their families. The nurse is believed to play an important role in this process, but nurse perceptions and experiences have not been well-described.

Purpose: Provide an exploration of pediatric oncology nurses' experiences with prognosis-related communication (PRC). Read More

View Article
November 2018
1 Read

Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature.

Clin Breast Cancer 2018 Nov 14. Epub 2018 Nov 14.

Department of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

View Article
November 2018

Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass.

Cell Stem Cell 2018 Dec;23(6):775-776

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

In this issue of Cell Stem Cell, Petrillo et al. (2018) improve lentiviral transduction of hematopoietic stem cells (HSCs) by using cyclosporine H to relieve viral entry restriction by interferon-induced transmembrane protein 3 (IFITM3). This finding promises to enhance the efficiency of ex vivo therapeutic gene transfer and gene editing of HSCs. Read More

View Article
December 2018

Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC.

Chin Clin Oncol 2018 Nov 9. Epub 2018 Nov 9.

Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.

View Article
November 2018

CD30+ T-cell lymphoproliferative disorders.

Chin Clin Oncol 2018 Oct 11. Epub 2018 Oct 11.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

The term "CD30+ T-cell lymphoproliferative disorders" describes a group of diverse diseases of the skin, subcutaneous tissues and mucosa that range from lesions requiring clinical observation to those necessitating systemic cytotoxic chemotherapy. Careful consideration of both clinical and histopathologic presentation is needed for appropriate diagnosis and treatment. This review will present the current classification of these disorders and potential treatment paradigms. Read More

View Article
October 2018
2 Reads

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Biol Blood Marrow Transplant 2018 Dec 3. Epub 2018 Dec 3.

Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Non-graft-versus-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. Read More

View Article
December 2018
7 Reads

A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.

Cancer 2018 Dec 6. Epub 2018 Dec 6.

Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Background: Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm characterized by the presence of abnormal CD1a-positive (CD1a )/CD207 histiocytes. Hemophagocytic lymphohistiocytosis (HLH) represents a spectrum of hyperinflammatory syndromes typified by the dysregulated activation of the innate and adaptive immune systems. Patients with LCH, particularly those with multisystem (MS) involvement, can develop severe hyperinflammation mimicking that observed in HLH. Read More

View Article
December 2018
1 Read